The study confirms that the vaccine induces a strong immune response both systemically and in mucosal tissues, leading to effective protection against disease, states the company.

One year ago, Abera Bioscience announced its commitment to developing a nasal influenza vaccine, aiming to provide broader protection against respiratory viruses and enhance readiness for future pandemics. Now, one year later, preclinical data show that the vaccine candidate offers robust protection, including 100% survival in the vaccinated mice group following influenza virus challenge, compared to 80% mortality in the unvaccinated group, no detectable virus in either the nose or lungs, and high antibody levels both systemically and in mucosal tissues.

“Achieving such strong results on the first attempt – within just one year from decision and on a limited budget – clearly demonstrates the strength of our platform. During this year, we have also relocated our laboratory, expanded our internal capabilities, and advanced multiple development projects in parallel,” says Maria Alriksson, CEO, Abera Bioscience.

Collaboration with CEPI

This study was conducted as part of Abera’s collaboration with CEPI (Coalition for Epidemic Preparedness Innovations), which funds the company’s influenza research. In this study, well-characterized influenza antigens were used as a model to assess the vaccine’s potential to protect against future pandemic influenza threats.

Abera intends to present the full results in a peer-reviewed scientific journal and will also share data with existing and potential partners under NDA, they state.